Literature DB >> 15975726

Delta9-tetrahydrocannabinol increases C6 glioma cell death produced by oxidative stress.

I Goncharov1, L Weiner, Z Vogel.   

Abstract

(-)Delta9-tetrahydrocannabinol is a scavenger of free radicals. However, the activation of the CB1 receptor in cultured C6 glioma cells by (-)delta9-tetrahydrocannabinol in the presence of reagents generating reactive oxygen species leads to amplification of the cellular damage from oxidative stress. This was evident by increased loss of cell wall integrity, impaired mitochondrial function and reduction of glucose uptake. In addition, (-)delta9-tetrahydrocannabinol treatment was also found to be deleterious to the cells under conditions of glucose starvation. Free radicals have been implicated in various conditions leading to cell death and, as a routine, the Fenton reaction is utilized for modeling reactive oxygen species production. Our study was performed using a cell permeating Fe(III) chelating quinone that provides more physiological conditions for mimicking the naturally occurring oxidative stress within the cell and thus serves as a better model for natural reactive oxygen species formation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15975726     DOI: 10.1016/j.neuroscience.2005.04.042

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  16 in total

Review 1.  Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.

Authors:  Janos Paloczi; Zoltan V Varga; George Hasko; Pal Pacher
Journal:  Antioxid Redox Signal       Date:  2017-07-18       Impact factor: 8.401

2.  Dual neuroprotective and neurotoxic effects of cannabinoid drugs in vitro.

Authors:  Anastasia Bologov; Mikhal Gafni; Ora Keren; Yosef Sarne
Journal:  Cell Mol Neurobiol       Date:  2010-11-04       Impact factor: 5.046

3.  Marijuana effects on changes in brain structure and cognitive function among HIV+ and HIV- adults.

Authors:  April D Thames; Taylor P Kuhn; Timothy J Williamson; Jacob D Jones; Zanjbeel Mahmood; Andrea Hammond
Journal:  Drug Alcohol Depend       Date:  2016-11-14       Impact factor: 4.492

4.  The G1359A-CNR1 gene polymorphism is associated to glioma in Spanish patients.

Authors:  Mercedes Núñez; Sandra Perdomo; Juan Moreta; Ángel Santos-Briz; Rogelio González-Sarmiento
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

5.  Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells.

Authors:  Ana Juknat; Maciej Pietr; Ewa Kozela; Neta Rimmerman; Rivka Levy; Giovanni Coppola; Daniel Geschwind; Zvi Vogel
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 6.  Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue.

Authors:  Eiron Cudaback; Nephi Stella
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

Review 7.  The endocannabinoid system in normal and pathological brain ageing.

Authors:  Andras Bilkei-Gorzo
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

Review 8.  Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas.

Authors:  Francisco Carlos Machado Rocha; Jair Guilherme Dos Santos Júnior; Sergio Carlos Stefano; Dartiu Xavier da Silveira
Journal:  J Neurooncol       Date:  2013-10-20       Impact factor: 4.130

Review 9.  Endocannabinoids and reactive nitrogen and oxygen species in neuropathologies.

Authors:  Allyn C Howlett; Somnath Mukhopadhyay; Derek C Norford
Journal:  J Neuroimmune Pharmacol       Date:  2006-06-24       Impact factor: 4.147

10.  Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.

Authors:  N Olea-Herrero; D Vara; S Malagarie-Cazenave; I Díaz-Laviada
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.